We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea

This study has suspended participant recruitment.
(It was not possible to recruit enough patients with obstructive sleep apnea.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00438412
First Posted: February 22, 2007
Last Update Posted: April 22, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Regional Hospital Holstebro
  Purpose

The mechanisms involved in development and maintenance of hypertension in obstructive sleep apnea are not clarified.

We hypothesize that patients with obstructive sleep apnea have an abnormal level of some vasoactive hormones during apneic events during sleep.


Condition Phase
Obstructive Sleep Apnea Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Regional Hospital Holstebro:

Estimated Enrollment: 40
Study Start Date: October 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Adults, males and females,age 30 -65
Criteria

Patients with Obstructive sleep apnea

Inclusion Criteria:

  • Severe obstructive sleep apnea (apnea-hypopnea index > 30)

Exclusion Criteria:

  • Drug or alcohol abuse
  • Pregnancy
  • History or clinical signs of disease in the heart, lungs, brain, liver, kidneys or endocrine organs
  • Diabetes

Healthy Controls

Inclusion Criteria:

  • Apnea-hypopnea index < 10

Exclusion criteria:

  • Drug or alcohol abuse
  • Pregnancy
  • History or clinical signs of disease in the heart, lungs, brain, liver, kidneys or endocrine organs
  • Diabetes
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00438412


Locations
Denmark
Department of Medical Research, Holstebro Hospital
Holstebro, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Study Chair: Erling B Pedersen, Professor Regional Hospital Holstebro
  More Information

Responsible Party: Pia Holland Gjørup, Department of Medical Research
ClinicalTrials.gov Identifier: NCT00438412     History of Changes
Other Study ID Numbers: MED.RES.HOS.2006.01.PHH
First Submitted: February 20, 2007
First Posted: February 22, 2007
Last Update Posted: April 22, 2008
Last Verified: April 2008

Keywords provided by Regional Hospital Holstebro:
Noradrenalin
Endothelin-1
Angiotensin II
Arginine vasopressin
Aldosterone
Renin
Atrial natriuretic peptide
Brain natriuretic peptide
Blood pressure
Apnea

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases